Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced a collaboration with Obsidian Therapeutics to provide semi-mechanistic models and analysis services.  Applied BioMath will create semi-mechanistic models, using in vitro and in vivo preclinical data, to aid in dose prediction and knowledge gap identification for Obsidian's promising therapeutic strategy.  "Our Destablizing Domain platform is exceedingly powerful but also ph

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, today announced their participation and sponsorship at Canines-N-Kids Foundation's Paws for a Cure Research Symposium occurring November 12-13, 2018 at the Merck Research Laboratories in Boston, MA. 

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, today announced their participation at PharmSci 360 occurring November 4-7, 2018 in Washington, D.C.

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, today announced their upcoming webinar titled "QSP Approaches to Determine Best in Class Properties for Targeted Anabolic Growth Factor to Arthritic Joints" is airing live Thursday, November 8, 2018 at 2p.m. ET / 11a.m. PT.

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, today announced the speaker for the QSP Industry & Academia Symposium occurring Thursday, October 25, 2018 from 5:45-8:00 p.m. at the Cambridge Innovation Center, 101 Main Street location, in Cambridge, MA.

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, today announced four of their posters are accepted to present at ACoP9 occuring October 7-10, 2018 in San Diego, CA. 

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, today announced their participation in two speaking sessions at ACoP9 occurring October 7-10, 2018 in San Diego, CA.

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, today announced their participation as a sponsor at the Pharmaceutical and Bioscience Society (PBSS) San Francisco Antibody Drug Conjugate (ADC) workshop being held Wednesday September 12, 2018 at 8:45 a.m. at the SF Bay Area: Foster City Crowne Plaza in San Francisco, CA.

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, today announced their upcoming webinar titled "A Lipid Nanoparticle Quantitative Systems Pharmacology (QSP) Case Study". The webinar airs live Wednesday, September 12, 2018 at 2p.m. ET / 11a.m. PT.

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, today announced their participation at the 9^th annual World Bispecific Summit occurring September 19-20, 2018 in Boston, MA.

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, today announced an extension to their collaboration with Northern Biologics Inc. to include Phase I clinical analyses for MSC-1, their lead antibody therapeutic targeting the cytokine LIF for the treatment of cancer.

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to de-risk and accelerate drug research and development, today announced a collaboration with Revitope for an in-vitro and human mechanistic PK/PD modeling of Revitope's bispecific T Cell Engaging Antibody Circuits (TEAC) targeting solid tumors.  "TEAC are designed to increase tumor specificity and launch an immune activation only when bound to the cancer cell surface.

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced a collaboration with Sanofi for the analysis of systems pharmacology pharmacokinetic (PK)/target engagement (TE) models for bispecific antibody combinations.  Applied BioMath will help assess the risk and feasibility of multispecific combinations and compare them to fixed dose combinations (FDC) for multiple targets.  These analyses will be used to help prioritize the portfolio and provide early screening criteria for lead generation.  

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced a collaboration with Sanofi to develop quantitative systems pharmacology (QSP) models in immuno-oncology.   Applied BioMath will leverage its proprietary modeling platform to develop QSP pharmacokinetic (PK) and pharmacodynamics (PD) models for multiple therapeutics in both animal and human species.

Applied BioMath, the industry-leader in applying mechanistic modeling to drug research and development, today announced that CytomX has once again chosen Applied BioMath for the development of their semi-mechanistic pharmacokinetic (PK) and pharmacodynamic (PD) models of human for immuno-oncology.  "Our choice of Applied BioMath for continued QSP model development reflects a track record of past successes with high-quality, innovative, and timely deliverables.

[Webinar] Quantitative Modeling and Simulation Approaches: Driving Critical Decisions from Research through Clinical Trials
November 7, 2017 | 1 pm to 2 pm ET
Hosted by: Cambridge Healthtech Institute 

Applied BioMath, the industry-leader in applying mechanistic modeling to drug research and development, today announced that they have been awarded a grant for development of a quantitative systems pharmacology model of amyloid beta and tau pathways for clinical trial design and decision making in Alzheimer's Disease and Dementia.

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced their participation at the annual Drug Development Boot Camp November 15-16, 2017 at the Harvard Club in Boston, MA. The Drug Development Boot Camp is hosted by Speid & Associates, Inc., in coordination with Harvard’s Office of Technology Development, and is a two-day intensive program for executive-level individuals that involves hands-on learning about the drug development process. 

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic systems modeling, simulation, and analysis to de-risk drug research and development, today announces their upcoming participation at PEGS: The Essential Protein Engineering Summit being held April 30 - May 4, 2018 in Boston, MA. Applied BioMath is sponsoring, exhibiting, presenting a poster, and presenting two talks at the conference.

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic mathematical modeling, simulation, and analysis to de-risk therapeutic research and development, today announced a collaboration with Checkpoint Therapeutics, Inc., for semi-mechanistic pharmacokinetic and pharmacodynamic (PK/PD) modeling in advanced metastatic solid tumors.   

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a collaboration with Xencor to perform semi-mechanistic PK/PD modeling to analyze Xencor's XmAb® IL15/IL15Rα-Fc program for the treatment of solid tumors.  The collaboration will focus on developing a mathematical model relating XmAb®24306 modulated potency and extended half-life to observed pharmacokinetics and in vivo T-cell stimulation.

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, today announced a collaboration with Pandion Therapeutics for semi-mechanistic pharmacokinetic and target occupancy (PK/TO) modeling in Autoimmune Disease.

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to drug research and development, today announced their newest Science Advisory Board member, Dhaval K. Shah, PhD.

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced a collaboration with Compass Therapeutics for the semi-mechanistic pharmacokinetic and pharmacodynamic (PK/PD) modeling of a therapeutic targeting solid tumors.  Semi-mechanistic PK/PD models will be developed for mouse, cynomolgus monkey, and human species and will help answer strategic questions such as the target coverage required for efficacy and dose regimen selection for the clinical study.